NASDAQ Soins de santé Biotechnologie TRVI

Trevi Therapeutics, Inc.

$ 17.21 5.13 %

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.

CEO: Jennifer L. Good - https://www.trevitherapeutics.com

Summary 30-Y Financials Dividend Analyst Historique indicateurs Possession / Senat
Price objectif

$25 45.26 %

Recommandation

Buy

DCF

$ 0.11

Loading data...

TRVI vs S&P500

Loading data...

No data available.

Quick ratio

24.75

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-53.78

may indicate that the company is undervalued or has poor growth prospects.

EPS

-0.32

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-24.53 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-30.49 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

9.17

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.00

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

-0.22

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
2 indicates worrying financial health
Altman score
193.64 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
2.73 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.00 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.